Michael A. Medici joined Summit Partners in 2005. Prior to Summit, he worked for Prudential Capital Group.
Based in Summit’s Boston office, Michael is active in the firm’s investment activities in North America, Europe and Asia. His board directorships and investments include Accedian Networks, Anesthetix Holdings (acquired by TeamHealth), ApoCell, Diagnostic Hybrids (acquired by Quidel Corporation), Fermentas International (acquired by Thermo Fisher Scientific), Hiperos, LogiXML, PeerApp and Telerik.
Michael received a BS in finance and international business from Georgetown University.